top of page

AACR24: Having entered the clinic last night, Nested's CEO discusses the preclinical profile of a brain-penetrant, pan-RAF/MEK molecular glue

Disclosing to BiotechTV that the program has dosed its first patient last night, Darrin Miles describes how this molecular glue therapy has been designed to bind to MEK and all isoforms of MEK and RAF in combination.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page